May 2, 2024 | Access, clinical trials, digital health, digital tools, oncology, patient insight-gathering, reimbursement
With rapid growth comes growing pains…

The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.
New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.
With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.
Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Natalie Yeadon, CEO & Co-Founder at Impetus Digital, provides insight into how COVID has changed clinical trials.
Natalie Yeadon, Co-Founder & CEO at Impetus Digital, provides insight on how to inspire creativity with virtual working groups.
Learn how a Pharma team engaged both dermatologists and patients with psoriasis in two parallel virtual advisory boards.
Natalie Yeadon, Co-Founder & CEO at Impetus Digital, provides insight on Facial Recognition Software in Healthcare.
Dr. Zayna Khayat, Future Strategist at SE Health, dives into the future of aging and healthcare in Canada, including the roles of emerging technologies, the shift to people-powered healthcare, and…
Dr. Shahar Keinan, Co-founder & CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve…
Ten easy steps that individual medical, marketing, clinical, regulatory, and market access teams can take to reduce their own footprints.
Christine Whiteside, COO of VoxCell BioInnovation, discusses 3D bioprinting, including current and future applications and key barriers to realizing its full potential. She also shares her tips for getting new…
Dr. Verena Voelter, Founder & Managing Director at 5P Health Care Solutions, explores collaborative value-based healthcare models, the role of digital transformation in enabling new forms of patient-centric and value-generating…
Robert Galarza, CEO of TruTrace Technologies, Inc., dives into the use of blockchain technology for verifying medical cannabis products and protecting intellectual property. He also shares his leadership tips and…
